These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28094372)

  • 1. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
    Liang D; Chen Q; Guo Y; Zhang T; Guo W
    Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
    Pan YL; Liu YL; Chen JZ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of the human fibroblast growth factor receptor 4 kinase.
    Lesca E; Lammens A; Huber R; Augustin M
    J Mol Biol; 2014 Nov; 426(22):3744-3756. PubMed ID: 25219510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.
    Yosaatmadja Y; Patterson AV; Smaill JB; Squire CJ
    Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):525-33. PubMed ID: 25760602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
    Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
    PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
    Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
    Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
    Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3.
    Hwang G; Kim H; Yoon H; Song C; Lim DK; Sim T; Lee J
    Int J Nanomedicine; 2017; 12():5345-5357. PubMed ID: 28794627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
    Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
    Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
    Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
    Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
    Ryan MR; Sohl CD; Luo B; Anderson KS
    Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.